Shares of Codexis, Inc. (NASDAQ:CDXS – Get Free Report) have earned an average rating of “Hold” from the five ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $6.00.
Several research firms have recently weighed in on CDXS. Piper Sandler reduced their price objective on Codexis from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, August 17th. Wall Street Zen upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings raised shares of Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 23rd. Benchmark restated a “hold” rating on shares of Codexis in a research report on Thursday, August 20th. Finally, Stephens restated an “overweight” rating and issued a $5.00 price target on shares of Codexis in a research report on Monday.
Get Our Latest Analysis on CDXS
Institutional Investors Weigh In On Codexis
Several hedge funds have recently made changes to their positions in the stock. Empowered Funds LLC acquired a new stake in Codexis during the third quarter worth about $160,000. Private Advisor Group LLC acquired a new position in Codexis in the 3rd quarter valued at approximately $1,677,000. Aberdeen Group plc raised its holdings in Codexis by 59.5% in the 3rd quarter. Aberdeen Group plc now owns 10,797,702 shares of the biotechnology company’s stock valued at $15,009,000 after acquiring an additional 4,027,748 shares in the last quarter. Prescott Group Capital Management L.L.C. acquired a new position in Codexis in the 3rd quarter valued at approximately $556,000. Finally, Post Resch Tallon Group Inc. lifted its position in shares of Codexis by 1.9% in the 3rd quarter. Post Resch Tallon Group Inc. now owns 573,953 shares of the biotechnology company’s stock worth $798,000 after acquiring an additional 10,475 shares during the period. Institutional investors own 78.54% of the company’s stock.
Codexis Stock Down 1.7%
Shares of CDXS stock traded down $0.02 on Monday, hitting $1.14. The company’s stock had a trading volume of 139,915 shares, compared to its average volume of 1,387,668. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.06 and a quick ratio of 2.99. Codexis has a fifty-two week low of $0.90 and a fifty-two week high of $2.98. The firm’s fifty day moving average price is $1.29 and its 200-day moving average price is $1.78. The stock has a market capitalization of $124.84 million, a price-to-earnings ratio of -5.70 and a beta of 2.38.
Codexis (NASDAQ:CDXS – Get Free Report) last posted its earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. The firm had revenue of $19.26 million for the quarter, compared to the consensus estimate of $18.72 million. Codexis had a negative net margin of 21.77% and a negative return on equity of 45.54%. Research analysts anticipate that Codexis will post -0.37 EPS for the current year.
Codexis Company Profile
Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.
Featured Stories
- Five stocks we like better than Codexis
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.
